- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book is the first to focus on Bayesian phase I-II clinical trials. It describes many problems with the conventional phase I-phase II paradigm and covers a large number of modern Bayesian phase I-II clinical trial designs.
Andere Kunden interessierten sich auch für
- Design and Analysis of Clinical Trials for Predictive Medicine139,99 €
- Richard ChinAdaptive and Flexible Clinical Trials136,99 €
- Diane L FaircloughDesign and Analysis of Quality of Life Studies in Clinical Trials182,99 €
- Mark ChangInnovative Strategies, Statistical Solutions and Simulations for Modern Clinical Trials154,99 €
- Shein-Chung ChowAdaptive Design Methods in Clinical Trials198,99 €
- Clinical Trial Optimization Using R136,99 €
- Sin-Ho JungRandomized Phase II Cancer Clinical Trials138,99 €
-
-
-
This book is the first to focus on Bayesian phase I-II clinical trials. It describes many problems with the conventional phase I-phase II paradigm and covers a large number of modern Bayesian phase I-II clinical trial designs.
Produktdetails
- Produktdetails
- Verlag: CRC Press
- Seitenzahl: 324
- Erscheinungstermin: 22. Juni 2016
- Englisch
- Abmessung: 236mm x 154mm x 25mm
- Gewicht: 607g
- ISBN-13: 9781498709552
- ISBN-10: 1498709559
- Artikelnr.: 44495715
- Verlag: CRC Press
- Seitenzahl: 324
- Erscheinungstermin: 22. Juni 2016
- Englisch
- Abmessung: 236mm x 154mm x 25mm
- Gewicht: 607g
- ISBN-13: 9781498709552
- ISBN-10: 1498709559
- Artikelnr.: 44495715
Ying Yuan is a professor and co-chief of the Section of Adaptive Clinical Trials in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct associate professor in the Department of Statistics at Rice University. Dr. Yuan has published over 100 peer-reviewed research papers in top statistical and medical journals. He is an associate editor of Biometrics and a board member of the International Chinese Statistical Association. He received his PhD in biostatistics from the University of Michigan. His research interests include Bayesian adaptive clinical trial design, statistical analysis of missing data, and Bayesian statistics. Hoang Q. Nguyen is a senior computational scientist in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He received his PhD in computational and applied mathematics from Rice University. His research interests include Bayesian clinical trial design, computational algorithms, regression modeling, and Bayesian data analysis. Peter F. Thall is the Anise J. Sorrell Professor in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct professor in the Department of Statistics at Rice University. Dr. Thall is a fellow of the American Statistical Association (ASA) and the Society for Clinical Trials, an associate editor for Clinical Trials and Statistics in Biosciences, and an ASA Media Expert. He has published over 200 papers and book chapters in the statistical and medical literature. He received his PhD in statistics and probability from the Florida State University. His research interests include clinical trial design, dynamic treatment regimes, prior elicitation, Bayesian nonparametric statistics, and personalized medicine.
Why Conduct Phase I
II Trials? The Phase I
II Paradigm. Establishing Priors. Efficacy
Toxicity Trade
Off
Based Designs. Designs with Late
Onset Outcomes. Utility
Based Designs. Personalized Dose Finding. Combination Trials. Optimizing Molecularly Targeted Agents. Optimizing Doses in Two Cycles. Optimizing Dose and Schedule. Dealing with Dropouts. Optimizing Intra
Arterial tPA. Optimizing Sedative Dose in Preterm Infants. Bibliography.
II Trials? The Phase I
II Paradigm. Establishing Priors. Efficacy
Toxicity Trade
Off
Based Designs. Designs with Late
Onset Outcomes. Utility
Based Designs. Personalized Dose Finding. Combination Trials. Optimizing Molecularly Targeted Agents. Optimizing Doses in Two Cycles. Optimizing Dose and Schedule. Dealing with Dropouts. Optimizing Intra
Arterial tPA. Optimizing Sedative Dose in Preterm Infants. Bibliography.
Why Conduct Phase I
II Trials? The Phase I
II Paradigm. Establishing Priors. Efficacy
Toxicity Trade
Off
Based Designs. Designs with Late
Onset Outcomes. Utility
Based Designs. Personalized Dose Finding. Combination Trials. Optimizing Molecularly Targeted Agents. Optimizing Doses in Two Cycles. Optimizing Dose and Schedule. Dealing with Dropouts. Optimizing Intra
Arterial tPA. Optimizing Sedative Dose in Preterm Infants. Bibliography.
II Trials? The Phase I
II Paradigm. Establishing Priors. Efficacy
Toxicity Trade
Off
Based Designs. Designs with Late
Onset Outcomes. Utility
Based Designs. Personalized Dose Finding. Combination Trials. Optimizing Molecularly Targeted Agents. Optimizing Doses in Two Cycles. Optimizing Dose and Schedule. Dealing with Dropouts. Optimizing Intra
Arterial tPA. Optimizing Sedative Dose in Preterm Infants. Bibliography.